Cancer Gene Therapy Market Synopsis

Cancer Gene Therapy Market Size Was Valued at USD 3.9 Billion in 2023, and is Projected to Reach USD 18.4 Billion by 2032, Growing at a CAGR of 18.8% From 2024-2032.

Cancer Gene Therapy Market deals with the strategic business domain of healthcare industry that deals with the therapies which deal with genetic modification of patient’s cells to combat cancer. This approach usually seeks to either restore normal genes, which are produced by cancer causing genes or silence genes that instigate cancer or put in different genes that are able to fight cancer. Such technologies as Gene Augmentation, Gene Editing to Gene Silencing which pertain to technologies that are essential in enhancing cancer prognosis and better odds of survival for patients having different type of cancers.

• Cancer gene therapy market is a fast emerging market, which is the result of innovations of biotechnology and genetic engineering. This kind of market is unique due to the high rate of technological advancement in therapy that has several ongoing clinical trials to treat different kinds of cancer. They added that the market will continue to experience growth because the rate of cancer cases is rising, there is a growing interest in personalized medicine; and gene therapies are considered more as a viable solution to diseases than before. Governments and private players thus are investing continuously for the cancer related products; this investment is again fueling the market tremendously. Yet the market also remains quite regulated and the rules and requirements for growing and implementing gene therapies might turn into a barrier from time to time due to which the entry of new products can be hampered.
• Despite this there is great potential for future growth in the Cancer Gene Therapy Market due to advancement in the use of CRISPR, viral vectors and non-viral gene delivery mechanisms. The market is very intense with big and small firms involved in genetherapies development along with some pharmaceutical firms, biotechnology firms and research institutions among which the major aims to deliver the best and safest therapies. Additionally, relationships, and alliances between related industries are established in that firms opt to work together so as to complement efforts and facilities so as to enhance the discovery of new approaches to treatment. The market seems set to expand further as more gene therapies are likely to gain approval in the next few years providing a new hope to millions of cancer sufferers across the globe.

Cancer Gene Therapy Market Trend Analysis

The Rise of Immuno-Gene Therapy

• Perhaps one of the most important trends in the development of the Cancer Gene Therapy Market is immuno-gene therapy which is a relatively novel type of gene therapy that is infused with immunotherapy.. This completely different approach to treatment involves the process of modifying a patient’s immune system to improve its capacity to identify and attack cancer cells. CAR-T cell therapy that attempts to customize T cells to pointed cancer antigens remain useful in clinical assessments, and there are high outcomes in patients with blood cancer like leukemia and lymphoma. This trend is expected to continue gaining momentum as the role of the viral vector in the treatment of solid tumors is investigated, which have been previously difficult to deal with concerning usual gene therapies.

Expanding Horizons in Emerging Markets

• The Cancer Gene Therapy Market is full of opportunities especially in the developing markets where incidence of cancer diseases is high and there is poor availability of advanced therapy treatments. Further, there are growth in the health care infrastructure and increment in the health care costs and hence more and more complex treatments have become available to the patients. Thus, those companies that are capable to fit regulatory solutions and approaches to popular PEMs, as well as provide efficient and relatively cheap solutions, will be provided with deep competitive advantages in such emergent markets.

Cancer Gene Therapy Market Segment Analysis:

Cancer Gene Therapy Market Segmented on the basis of Therapy and End Use.

By Therapy, Oncolytic Virotherapy segment is expected to dominate the market during the forecast period

• The Oncolytic Virotherapy segment will continue to hold the largest market share of the Cancer Gene Therapy Market in the given time span owing to its novel approach of dealing with cancer. Compared with conventional therapies, this kind of therapy not only can directly kill cancer cells but also make body immune system identify and destroy the tumor, thus it has brought double changes for body and shows higher efficacy. Since several oncolytic viruses have been approved to be used clinically, along with a large number of candidates in different phases of clinical trials, this segment is quickly emerging. It also stated that the effectiveness of therapies such as T-VEC (Talimogene laherparepvec) has created the right conditions for further work in the direction of this development., driven by its innovative approach to treating cancer.

By End Use, Biopharmaceutical Companies segment expected to held the largest share

• The Biopharmaceutical Companies segment is also expected to dominate the Cancer Gene Therapy Market by end use due to a central function of these companies in the discovery, marketing, and sale of gene therapies. As for biopharmaceutical organizations, they are the major trendy movers and shakers in the marketplace because those organizations are the major investors in research and development of new gene therapies to address needs in the oncology segment. They have significant knwledgein genetic engineering and good financial base that enables them to undergo broad clinical research, approvals and commercialize developed therapies and drugs from the laboratory setting to patients.
• However, these companies also form alliances with academic institutions and small biotechnology companies whereby they can access state-of-art technologies and new product opportunities. Increased interest in differentiated treatment and individualized cancer therapy contributes to biopharmaceutical companies’ leadership in the cancer gene therapy sector because they are best suited to address the requirements of the market. The given options indicate that biopharmaceutical companies will continue to dominate delivering on their strengths and bringing innovations that are crucial to meet the needs of oncology in the coming years.

Cancer Gene Therapy Market Regional Insights:

Asia Pacific is Expected to Dominate the Market Over the Forecast period

• By the year 2023 North America still remain the largest region that contributes to Cancer Gene Therapy Market, and this is due to sound health facilities, increased funding on research and development as well as the companies dealing with biotechnology and pharmaceuticals. The United States has been identified as the leading express carrier, offering more than 45% market share. This is because United States has well-developed health-care system, high incidence of cancer and support from major government bodies like FDA that have made it easy for innovative therapy to gain approval. The aforesaid university research institutions and highly skilled human resources strengthen the leadership of this region in the market. Also, there is a preview of the leading North American organogenomics companies that have been advancing and commercializing new gene therapies and consequently boosting the supremacy of the North American market.

Active Key Players in the Cancer Gene Therapy Market

• Adaptimmune Therapeutics plc (United Kingdom)
• Amgen Inc. (United States)
• BioNTech SE (Germany)
• Bluebird Bio, Inc. (United States)
• Cellectis S.A. (France)
• CRISPR Therapeutics AG (Switzerland)
• Genenta Science (Italy)
• Gilead Sciences, Inc. (United States)
• Intellia Therapeutics, Inc. (United States)
• Mustang Bio, Inc. (United States)
• Novartis AG (Switzerland)
• Orchard Therapeutics plc (United Kingdom)
• Sangamo Therapeutics, Inc. (United States)
• Spark Therapeutics, Inc. (United States)
• Ziopharm Oncology, Inc. (United States) and Other key Players

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: Cancer Gene Therapy Market by Therapy
 4.1 Cancer Gene Therapy Market Snapshot and Growth Engine
 4.2 Cancer Gene Therapy Market Overview
 4.3 Oncolytic Virotherapy
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Oncolytic Virotherapy: Geographic Segmentation Analysis
 4.4 Gene Induced Immunotherapy
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Gene Induced Immunotherapy: Geographic Segmentation Analysis
 4.5 Gene Transfer
  4.5.1 Introduction and Market Overview
  4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.5.3 Key Market Trends, Growth Factors and Opportunities
  4.5.4 Gene Transfer: Geographic Segmentation Analysis

Chapter 5: Cancer Gene Therapy Market by End Use
 5.1 Cancer Gene Therapy Market Snapshot and Growth Engine
 5.2 Cancer Gene Therapy Market Overview
 5.3 Research Institutes
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Research Institutes: Geographic Segmentation Analysis
 5.4 Biopharmaceutical Companies
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Biopharmaceutical Companies: Geographic Segmentation Analysis
 5.5 Diagnostic Centers
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Diagnostic Centers: Geographic Segmentation Analysis
 5.6 Others
  5.6.1 Introduction and Market Overview
  5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.6.3 Key Market Trends, Growth Factors and Opportunities
  5.6.4 Others: Geographic Segmentation Analysis

Chapter 6: Company Profiles and Competitive Analysis
 6.1 Competitive Landscape
  6.1.1 Competitive Benchmarking
  6.1.2 Cancer Gene Therapy Market Share by Manufacturer (2023)
  6.1.3 Industry BCG Matrix
  6.1.4 Heat Map Analysis
  6.1.5 Mergers and Acquisitions
  
 6.2 ADAPTIMMUNE THERAPEUTICS PLC (UNITED KINGDOM)
  6.2.1 Company Overview
  6.2.2 Key Executives
  6.2.3 Company Snapshot
  6.2.4 Role of the Company in the Market
  6.2.5 Sustainability and Social Responsibility
  6.2.6 Operating Business Segments
  6.2.7 Product Portfolio
  6.2.8 Business Performance
  6.2.9 Key Strategic Moves and Recent Developments
  6.2.10 SWOT Analysis
 6.3 AMGEN INC (UNITED STATES)
 6.4 BIONTECH SE (GERMANY)
 6.5 BLUEBIRD BIO INC (UNITED STATES)
 6.6 CELLECTIS S.A (FRANCE)
 6.7 CRISPR THERAPEUTICS AG (SWITZERLAND)
 6.8 GENENTA SCIENCE (ITALY)
 6.9 GILEAD SCIENCES INC (UNITED STATES)
 6.10 INTELLIA THERAPEUTICS INC (UNITED STATES)
 6.11 MUSTANG BIO INC (UNITED STATES)
 6.12 NOVARTIS AG (SWITZERLAND)
 6.13 ORCHARD THERAPEUTICS PLC (UNITED KINGDOM)
 6.14 SANGAMO THERAPEUTICS INC (UNITED STATES)
 6.15 SPARK THERAPEUTICS INC (UNITED STATES)
 6.16 ZIOPHARM ONCOLOGY INC (UNITED STATES)
 6.17 OTHER KEY PLAYERS

Chapter 7: Global Cancer Gene Therapy Market By Region
 7.1 Overview
 7.2. North America Cancer Gene Therapy Market
  7.2.1 Key Market Trends, Growth Factors and Opportunities
  7.2.2 Top Key Companies
  7.2.3 Historic and Forecasted Market Size by Segments
  7.2.4 Historic and Forecasted Market Size By Therapy
  7.2.4.1 Oncolytic Virotherapy
  7.2.4.2 Gene Induced Immunotherapy
  7.2.4.3 Gene Transfer
  7.2.5 Historic and Forecasted Market Size By End Use
  7.2.5.1 Research Institutes
  7.2.5.2 Biopharmaceutical Companies
  7.2.5.3 Diagnostic Centers
  7.2.5.4 Others
  7.2.6 Historic and Forecast Market Size by Country
  7.2.6.1 US
  7.2.6.2 Canada
  7.2.6.3 Mexico
 7.3. Eastern Europe Cancer Gene Therapy Market
  7.3.1 Key Market Trends, Growth Factors and Opportunities
  7.3.2 Top Key Companies
  7.3.3 Historic and Forecasted Market Size by Segments
  7.3.4 Historic and Forecasted Market Size By Therapy
  7.3.4.1 Oncolytic Virotherapy
  7.3.4.2 Gene Induced Immunotherapy
  7.3.4.3 Gene Transfer
  7.3.5 Historic and Forecasted Market Size By End Use
  7.3.5.1 Research Institutes
  7.3.5.2 Biopharmaceutical Companies
  7.3.5.3 Diagnostic Centers
  7.3.5.4 Others
  7.3.6 Historic and Forecast Market Size by Country
  7.3.6.1 Bulgaria
  7.3.6.2 The Czech Republic
  7.3.6.3 Hungary
  7.3.6.4 Poland
  7.3.6.5 Romania
  7.3.6.6 Rest of Eastern Europe
 7.4. Western Europe Cancer Gene Therapy Market
  7.4.1 Key Market Trends, Growth Factors and Opportunities
  7.4.2 Top Key Companies
  7.4.3 Historic and Forecasted Market Size by Segments
  7.4.4 Historic and Forecasted Market Size By Therapy
  7.4.4.1 Oncolytic Virotherapy
  7.4.4.2 Gene Induced Immunotherapy
  7.4.4.3 Gene Transfer
  7.4.5 Historic and Forecasted Market Size By End Use
  7.4.5.1 Research Institutes
  7.4.5.2 Biopharmaceutical Companies
  7.4.5.3 Diagnostic Centers
  7.4.5.4 Others
  7.4.6 Historic and Forecast Market Size by Country
  7.4.6.1 Germany
  7.4.6.2 UK
  7.4.6.3 France
  7.4.6.4 Netherlands
  7.4.6.5 Italy
  7.4.6.6 Russia
  7.4.6.7 Spain
  7.4.6.8 Rest of Western Europe
 7.5. Asia Pacific Cancer Gene Therapy Market
  7.5.1 Key Market Trends, Growth Factors and Opportunities
  7.5.2 Top Key Companies
  7.5.3 Historic and Forecasted Market Size by Segments
  7.5.4 Historic and Forecasted Market Size By Therapy
  7.5.4.1 Oncolytic Virotherapy
  7.5.4.2 Gene Induced Immunotherapy
  7.5.4.3 Gene Transfer
  7.5.5 Historic and Forecasted Market Size By End Use
  7.5.5.1 Research Institutes
  7.5.5.2 Biopharmaceutical Companies
  7.5.5.3 Diagnostic Centers
  7.5.5.4 Others
  7.5.6 Historic and Forecast Market Size by Country
  7.5.6.1 China
  7.5.6.2 India
  7.5.6.3 Japan
  7.5.6.4 South Korea
  7.5.6.5 Malaysia
  7.5.6.6 Thailand
  7.5.6.7 Vietnam
  7.5.6.8 The Philippines
  7.5.6.9 Australia
  7.5.6.10 New Zealand
  7.5.6.11 Rest of APAC
 7.6. Middle East & Africa Cancer Gene Therapy Market
  7.6.1 Key Market Trends, Growth Factors and Opportunities
  7.6.2 Top Key Companies
  7.6.3 Historic and Forecasted Market Size by Segments
  7.6.4 Historic and Forecasted Market Size By Therapy
  7.6.4.1 Oncolytic Virotherapy
  7.6.4.2 Gene Induced Immunotherapy
  7.6.4.3 Gene Transfer
  7.6.5 Historic and Forecasted Market Size By End Use
  7.6.5.1 Research Institutes
  7.6.5.2 Biopharmaceutical Companies
  7.6.5.3 Diagnostic Centers
  7.6.5.4 Others
  7.6.6 Historic and Forecast Market Size by Country
  7.6.6.1 Turkey
  7.6.6.2 Bahrain
  7.6.6.3 Kuwait
  7.6.6.4 Saudi Arabia
  7.6.6.5 Qatar
  7.6.6.6 UAE
  7.6.6.7 Israel
  7.6.6.8 South Africa
 7.7. South America Cancer Gene Therapy Market
  7.7.1 Key Market Trends, Growth Factors and Opportunities
  7.7.2 Top Key Companies
  7.7.3 Historic and Forecasted Market Size by Segments
  7.7.4 Historic and Forecasted Market Size By Therapy
  7.7.4.1 Oncolytic Virotherapy
  7.7.4.2 Gene Induced Immunotherapy
  7.7.4.3 Gene Transfer
  7.7.5 Historic and Forecasted Market Size By End Use
  7.7.5.1 Research Institutes
  7.7.5.2 Biopharmaceutical Companies
  7.7.5.3 Diagnostic Centers
  7.7.5.4 Others
  7.7.6 Historic and Forecast Market Size by Country
  7.7.6.1 Brazil
  7.7.6.2 Argentina
  7.7.6.3 Rest of SA

Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies

Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research